Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC - Trial NCT06031558
Access comprehensive clinical trial information for NCT06031558 through Pure Global AI's free database. This Phase 3 trial is sponsored by Shouyao Holdings (Beijing) Co. LTD and is currently Recruiting. The study focuses on Non-Small Cell Lung Cancer. Target enrollment is 120 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shouyao Holdings (Beijing) Co. LTD
Timeline & Enrollment
Phase 3
Jun 20, 2023
Jun 20, 2026
Primary Outcome
Assessment of ORR by independent review committee (IRC).
Summary
This is a phase III, open-label, single-arm, multicenter study designed to evaluate the
 anti-tumor activity and safety of SY-5007 administered orally to participants with locally
 advanced or metastatic RET-positive NSCLC.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06031558
Non-Device Trial